1. Pink Sheet
  2. >>Market Access

Pink Sheet Podcast: Taking A Look Back, And Forward, With US FDA’s Project Orbis

 
• By Pink Sheet Team

Pink Sheet reporters and editors in the US and Europe consider the growth and impact of Project Orbis after a year in which two major regulators joined the program, but several countries did not keep up with the US approval pace.

teamwork
Could Project Orbis expand beyond oncology in the coming years? • Source: Shutterstock

Pink Sheet senior writers Derrick Gingery and Eliza Slawther, Senior Editor Sue Sutter, Managing Editor Bridget Silverman, and Executive Editor Nielsen Hobbs discuss recent revelations about the approval totals among the Project Orbis partners compared to the US Food and Drug Administration and European Medicines Agency (:45), the program’s ongoing impact on global harmonization (9:15), and its potential to grow beyond oncology (16:49) in a look back at the program’s eventful year.

Open Media

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

EMA Explores Supporting Drug Development For High Unmet Need Disorder Scleroderma

 
• By Neena Brizmohun

While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.

EMA Nod For First MASH Drug Rezdiffra, Cell Therapy Zemcelpro And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.